Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Enveric Biosciences IncTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs Inovio Pharmaceuticals Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Inovio Pharmaceuticals Inc trades at $0.78 (market cap $76.09M). The key difference: Inovio Pharmaceuticals Inc is far larger — about 12.3× Enveric Biosciences Inc's market cap. Which is the better fit depends on your goals.

ENVBINO
Market Cap
$6.20M$76.09M
Sector
HealthHealth
52-Week High
$17.40$2.87
52-Week Low
$1.27$0.66
Enterprise Value
$1.30M$47.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.

Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.

Inovio Pharmaceuticals Inc

INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.

High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.

Returns comparison

Trailing returns across standard periods

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO